Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IAPP | P10997 | 2/20 | 0.31 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28526983 | 0.85 | GABRA1 (0.54) | GABRA1GABRB2AKR1B1ERN1L3MBTL1 | |
| SCHEMBL2042101 | 0.79 | IAPP (0.48) | GABRA1GABRB2AKR1B1ERN1IAPP | |
| SCHEMBL1738495 | 0.79 | MAPT (0.33) | MEN1MAPTKMT2A | |
| SCHEMBL3378789 | 0.78 | MMP2 (0.44) | GABRA1GABRB2AKR1B1ERN1L3MBTL1 | |
| SCHEMBL6068654 | 0.77 | GABRA1 (0.70) | GABRA1GABRB2L3MBTL1IAPP | |
| SCHEMBL8414772 | 0.77 | MAPT (0.32) | MAPT | |
| SCHEMBL18268986 | 0.76 | — | — | |
| SCHEMBL1115116 | 0.76 | ERN1 (0.52) | GABRA1GABRB2ERN1HMGB1 | |
| SCHEMBL3810019 | 0.76 | GABRA1 (0.66) | GABRA1GABRB2AKR1B1L3MBTL1MEN1 | |
| SCHEMBL2318046 | 0.76 | HSP90AA1 (0.49) | GABRA1GABRB2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | GABRA1 1364/4885GABRB2 428/4885AKR1B1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.